Perspective Therapeutics Inc. is a medical technology and radiopharmaceutical company which provide advanced treatment applications for cancers. The Company is the sole producer of Cesium-131 brachytherapy seeds. Perspective Therapeutics Inc., formerly known as Isoray Inc., is based in RICHLAND, Wash.
Revenue (Most Recent Fiscal Year) | $1.45M |
Net Income (Most Recent Fiscal Year) | $-79.28M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 136.24 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.70 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -5899.32% |
Net Margin (Trailing 12 Months) | -5790.08% |
Return on Equity (Trailing 12 Months) | -27.91% |
Return on Assets (Trailing 12 Months) | -24.00% |
Current Ratio (Most Recent Fiscal Quarter) | 17.02 |
Quick Ratio (Most Recent Fiscal Quarter) | 17.02 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.01 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $3.83 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.25 |
Earnings per Share (Most Recent Fiscal Year) | $-0.85 |
Diluted Earnings per Share (Trailing 12 Months) | -- |
Exchange | NYSEMKT |
Sector | Healthcare |
Industry | Medical Devices |
Common Shares Outstanding | 74.23M |
Free Float | 71.47M |
Market Capitalization | $200.42M |
Average Volume (Last 20 Days) | 0.72M |
Beta (Past 60 Months) | 1.11 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 3.72% |
Percentage Held By Institutions (Latest 13F Reports) | 54.66% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |